Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer

26 Dec 2024

Abstract excerpt

Dear Editor, Homologous recombination deficiency (HRD) is a potential biomarker for predicting the efficacy of platinum-based therapies, PARP inhibitor (PARPi) therapies and overall survival outcomes in epithelial ovarian cancer (EOC).1, 2 Nevertheless, the methodologies for HRD detection and the optimal timing for HRD assessment in tumour samples remain contentious and are infrequently examined within the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39724505
DOI: 10.1002/ctm2.70143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancerPMID 39724505Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and TreatmentSemantic proximity Read ↗

[Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing].Semantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity Read ↗

The clinical pathological characteristics and prognostic Relevance of Homologous Recombination Repair Gene Mutations in Ovarian Cancer Patients：A Retrospective Cohort StudySemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Association of homologous recombination repair gene mutation with clinical prognosis in histological subtypes of epithelial ovarian cancer patients.Semantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Benchmarking homologous recombination deficiency algorithms for prediction of clinical outcome in ovarian cancerSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.